Ascendis Pharma AS (STU:A710)
€ 220 (0%) Market Cap: 14.51 Bil Enterprise Value: 14.83 Bil PE Ratio: 29.67 PB Ratio: 27.64 GF Score: 22/100

Ascendis Pharma A/S at Leerink Global Healthcare Conference Transcript

Feb 25, 2020 / 04:30PM GMT
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Research Analyst

Good morning, everyone. Joe Schwartz, covering analyst for Ascendis. Very pleased to be joined by Jan Mikkelsen and Scott Smith, to give us an update at a very exciting time.

Questions & Answers

Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Research Analyst

Good morning, gentlemen. Maybe we can just ask you to give us a quick lay of the land before we dive into some more specifics around each of your programs.

Jan MÃ;ller Mikkelsen;S;President
Ascendis Pharma A;CEO, Member of Executive Board & Executive Director

¸ - /- -

First of all, thanks, Joe, for inviting us. It's always a pleasure to be here.

Yes. Ascendis Pharma, we have been executing the last years about our Vision 3x3, which is our strategic pathway how to be a leading biopharma company, and it's basic building a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot